RFAI · RF Acquisition Corp II
AI read · Neutral
The AI's read
RFAI shares exploded after shareholders approved a business combination with Singapore-based Nanyang Biologics, triggering a massive intraday gap. That matters because it turns a SPAC into an operating biotech and hands the market a clear event to price. The move is already huge — the stock is up roughly 216% intraday and sits near $40, with RSI in the mid-60s. That limits asymmetric upside unless new, material deal details or financing appear. Bottom line. We lean neutral: the catalyst is real and company-specific, but the market has largely priced it. Watch for closing timeline, redemptions, and dilution as the real drivers of next moves.